122 related articles for article (PubMed ID: 38905817)
41. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of the multi-strategy WHO emergency care toolkit in regional referral hospitals in Uganda.
Werner K; Risko N; Kalanzi J; Wallis LA; Reynolds TA
PLoS One; 2022; 17(12):e0279074. PubMed ID: 36516176
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.
Restelli U; Rizzardini G; Antinori A; Lazzarin A; Bonfanti M; Bonfanti P; Croce D
Ther Clin Risk Manag; 2017; 13():787-797. PubMed ID: 28721059
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda.
Zakiyah N; van Asselt ADI; Setiawan D; Cao Q; Roijmans F; Postma MJ
Appl Health Econ Health Policy; 2019 Feb; 17(1):65-76. PubMed ID: 30178267
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
Anderson SJ; Hsu CY; Ou HT; Ko NY; Yang CT; Lopes S
Value Health Reg Issues; 2021 May; 24():216-223. PubMed ID: 33857719
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
[TBL] [Abstract][Full Text] [Related]
48. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH
J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502
[TBL] [Abstract][Full Text] [Related]
49. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
50. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
[TBL] [Abstract][Full Text] [Related]
52. Potential cost-effectiveness of universal access to modern contraceptives in Uganda.
Babigumira JB; Stergachis A; Veenstra DL; Gardner JS; Ngonzi J; Mukasa-Kivunike P; Garrison LP
PLoS One; 2012; 7(2):e30735. PubMed ID: 22363480
[TBL] [Abstract][Full Text] [Related]
53. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.
Duarte HA; Babigumira JB; Enns EA; Stauffer DC; Shafer RW; Beck IA; Garrison LP; Chung MH; Frenkel LM; Bendavid E
EClinicalMedicine; 2020 May; 22():100355. PubMed ID: 32490370
[TBL] [Abstract][Full Text] [Related]
55. Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study.
Ayal MA; Berha AB
HIV AIDS (Auckl); 2023; 15():173-190. PubMed ID: 37139483
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
57. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
[TBL] [Abstract][Full Text] [Related]
58. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
[TBL] [Abstract][Full Text] [Related]
59. Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.
Berenguer J; Parrondo J; Landovitz RJ
PLoS One; 2019; 14(7):e0219802. PubMed ID: 31323075
[TBL] [Abstract][Full Text] [Related]
60. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
